T-group (topology)
218.2.1 Ribosomal protein L22
Ligands and drugs
3,499
Member domains
966
with ligand contacts (≤ 4 Å)
27.6% of members
562
with DrugDomain annotations
16.1% of members
60
with a DrugBank compound
1.7% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 218.2.1 belongs to X-group 218 Enolase-N/ribosomal protein, which binds 6.0 ligand superclasses per 20 proteins, narrower than 74% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00976 | TEL | Telithromycin | 14 |
| DB00199 | ERY | Erythromycin | 11 |
| DB00161 | VAL | Valine | 6 |
| DB01917 | PUT | Putrescine | 5 |
| DB00207 | ZIT | Azithromycin | 4 |
| DB00954 | DI0 | Dirithromycin | 3 |
| DB03566 | SPD | Spermidine | 3 |
| DB00127 | SPM | Spermine | 2 |
| DB00134 | MET | Methionine | 2 |
| DB09308 | EM1 | Solithromycin | 2 |
| DB00919 | SCM | Spectinomycin | 1 |
| DB01211 | CTY | Clarithromycin | 1 |
| DB01421 | PAR | Paromomycin | 1 |
| DB01972 | G | Guanosine-5'-Monophosphate | 1 |
| DB11475 | TYK | Tylosin | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 861 |
| CL | CHLORIDE ION | 70 |
| NAmetal | SODIUM ION | 68 |
| OHX | osmium (III) hexammine | 66 |
| SRmetal | STRONTIUM ION | 30 |
| Kmetal | POTASSIUM ION | 29 |
| SPD | SPERMIDINE | 27 |
| PUT | 1,4-DIAMINOBUTANE | 22 |
| UNX | UNKNOWN ATOM OR ION | 11 |
| SPM | SPERMINE | 9 |
| TEL | TELITHROMYCIN | 8 |
| MVM | N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)benzamide | 5 |
| TRP | TRYPTOPHAN | 5 |
| TYK | TYLOSIN | 4 |
| N2P | PENTANE-1,5-DIAMINE | 3 |
| OIY | Streptothricin D | 3 |
| SR0 | N~1~-(3-azaniumylpropyl)butane-1,4-diaminium | 3 |
| A1AE0 | 1-cyclopropyl-7-{7-[({[(3aR,4R,7R,8S,9S,10R,11R,13R,14E,15S,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-11-methoxy-14-(methoxyimino)-3a,7,9,11,13,15-hexamethyl-2,6-dioxododecahydro-2H,4H-[1,3]dioxolo[4,5-c]oxacyclotetradecin-8-yl]oxy}carbonyl)amino]hept-1-yn-1-yl}-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (non-preferred name) | 2 |
| A1AEZ | 1-cyclopropyl-7-[(4-{[3-({(3aR,4R,7R,8S,9S,10R,11R,13R,14E,15S,15aR)-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-11-methoxy-3a,7,9,11,13,15-hexamethyl-14-[({3-[5-(methylcarbamoyl)pyridin-3-yl]prop-2-yn-1-yl}oxy)imino]-2,6-dioxododecahydro-2H,4H-[1,3]dioxolo[4,5-c]oxacyclotetradecin-8-yl}oxy)-3-oxopropyl]amino}butyl)amino]-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (non-preferred name) | 2 |
| ERY | ERYTHROMYCIN A | 2 |